Avery Dennison has filed a lawsuit in Germany against UPM Raflatac, asserting that Raflex MDO(machine direction oriented) infringes European Patent Number 2049333 B1, Avery Dennison’s patent on its Global MDOTM pressure sensitive film product. In the suit, Avery
Dennison asks the German court to prevent UPM Raflatac from manufacturing, marketing, or selling Raflex MDO without a license. According to Avery Dennison, Global MDO is protected under patents granted in both Europe and China, and has patent applications
pending in the US and Brazil.
“Avery Dennison respects the intellectual property rights of other companies and individuals and expects others to do the same,” said Jeroen Diderich, vice president, global marketing, Avery Dennison Materials Group. “We attempted to negotiate a license agreement with
UPM Raflatac, in the hope of avoiding litigation while allowing their continued supply of this product. Unfortunately, that effort was unsuccessful.”
Avery Dennison’s Global MDO technology provides high conformability with a wide range of packaging shapes, while maintaining superior printing and decoration capabilities for converters and brand owners. The company has invested many years and significant resources in the research, development, and production of its MDO film portfolio. Global MDO film, launched in September 2011, is the latest development of the company’s highly successful MDO product family which has been marketed globally since 1995.
Countering Avery Dennison’s claim, UPM Raflatac says that during the past several years, it has been developing a number of products within the MDO film technology field that have resulted in several new inventions that are protected globally through patenting. Raflex MDO is an example of this development programme, creating a product that brings an alternative to the market place.
UPM Raflatac disputes that any infringement has occurred and has continuously sought to seek mutual understanding in this claim. In the absence of such understanding, UPM Raflatac will use every effort to protect itself against this claim and its right to continue the
manufacturing and supply of Raflex MDO to its customers.